AU2017235665B2 - Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists - Google Patents

Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists Download PDF

Info

Publication number
AU2017235665B2
AU2017235665B2 AU2017235665A AU2017235665A AU2017235665B2 AU 2017235665 B2 AU2017235665 B2 AU 2017235665B2 AU 2017235665 A AU2017235665 A AU 2017235665A AU 2017235665 A AU2017235665 A AU 2017235665A AU 2017235665 B2 AU2017235665 B2 AU 2017235665B2
Authority
AU
Australia
Prior art keywords
compound
group
pharmaceutically acceptable
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017235665A
Other languages
English (en)
Other versions
AU2017235665A1 (en
Inventor
James M. Cook
Guanguan LI
Michael Ming-Jin Poe
Miroslav M. SAVIC
Etienne Sibille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Belgrade - Faculty Of Pharmacy, University of
UWM Research Foundation Inc
Original Assignee
Centre for Addiction and Mental Health
Of Belgrade Faculty Of Pharmacy, University of
UWM Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health, Of Belgrade Faculty Of Pharmacy, University of, UWM Research Foundation Inc filed Critical Centre for Addiction and Mental Health
Publication of AU2017235665A1 publication Critical patent/AU2017235665A1/en
Priority to AU2022275446A priority Critical patent/AU2022275446B2/en
Application granted granted Critical
Publication of AU2017235665B2 publication Critical patent/AU2017235665B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2017235665A 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists Active AU2017235665B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022275446A AU2022275446B2 (en) 2016-03-18 2022-11-23 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAa receptor agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310409P 2016-03-18 2016-03-18
US62/310,409 2016-03-18
PCT/US2017/023206 WO2017161370A1 (en) 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022275446A Division AU2022275446B2 (en) 2016-03-18 2022-11-23 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAa receptor agonists

Publications (2)

Publication Number Publication Date
AU2017235665A1 AU2017235665A1 (en) 2018-09-27
AU2017235665B2 true AU2017235665B2 (en) 2022-12-08

Family

ID=59851645

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017235665A Active AU2017235665B2 (en) 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists
AU2022275446A Active AU2022275446B2 (en) 2016-03-18 2022-11-23 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAa receptor agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022275446A Active AU2022275446B2 (en) 2016-03-18 2022-11-23 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAa receptor agonists

Country Status (17)

Country Link
US (4) US10906909B2 (enExample)
EP (2) EP4129297A1 (enExample)
JP (2) JP7023876B2 (enExample)
AU (2) AU2017235665B2 (enExample)
CA (1) CA3016491A1 (enExample)
CY (1) CY1125576T1 (enExample)
DK (1) DK3439665T3 (enExample)
ES (1) ES2926918T3 (enExample)
HR (1) HRP20221098T1 (enExample)
HU (1) HUE059774T2 (enExample)
LT (1) LT3439665T (enExample)
PL (1) PL3439665T3 (enExample)
PT (1) PT3439665T (enExample)
RS (1) RS63674B1 (enExample)
SI (1) SI3439665T1 (enExample)
SM (1) SMT202200372T1 (enExample)
WO (1) WO2017161370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
US12636291B2 (en) * 2019-02-13 2026-05-26 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
JP2024533306A (ja) * 2021-09-08 2024-09-12 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 認知および気分症状の処置のためのイミダゾベンゾジアゼピン
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023059443A1 (en) * 2021-10-07 2023-04-13 Pantherics Incorporated Methods and compounds for treating inflammation
US20260125388A1 (en) * 2022-10-04 2026-05-07 Uwm Research Foundation, Inc. Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation
IT202400001089A1 (it) * 2024-01-22 2025-07-22 Fondazione St Italiano Tecnologia Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093466A1 (en) * 2007-10-03 2009-04-09 Bristol-Myers Squibb Company Carboxamide GABAa ALPHA2 Modulators
US20100004226A1 (en) * 2004-06-30 2010-01-07 Cook James M Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20100317619A1 (en) * 2002-03-28 2010-12-16 James Cook Selective Agents for Pain Suppression
US20150258128A1 (en) * 2011-04-28 2015-09-17 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4226768A (en) 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20030176456A1 (en) 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
USRE47475E1 (en) 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US7595395B2 (en) * 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
US20100130479A1 (en) 2005-05-16 2010-05-27 Cook James M Gabaergic Agents to Treat Memory Deficits
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
DE102006023554A1 (de) 2006-05-19 2007-11-22 Zf Friedrichshafen Ag Ermittlung der Drehzahl einer Getriebewelle
US8923318B2 (en) 2008-10-02 2014-12-30 Telefonaktiebolaget L M Ericsson (Publ) Wireless communication system and method for assigning a channel in said wireless communication system
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
WO2016154031A1 (en) 2015-03-20 2016-09-29 Uwm Research Foundation, Inc. Gabaergic ligands and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317619A1 (en) * 2002-03-28 2010-12-16 James Cook Selective Agents for Pain Suppression
US20100004226A1 (en) * 2004-06-30 2010-01-07 Cook James M Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20090093466A1 (en) * 2007-10-03 2009-04-09 Bristol-Myers Squibb Company Carboxamide GABAa ALPHA2 Modulators
US20150258128A1 (en) * 2011-04-28 2015-09-17 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAMJOSHI OJAS A ET AL, "Search for [alpha]3[beta]2/3[gamma]2 subtype selective ligands that are stable on human liver microsomes", BIOORGANIC & MEDICINAL CHEMISTRY, (2012-11-15), vol. 21, no. 1, pp 93-101 *

Also Published As

Publication number Publication date
AU2017235665A1 (en) 2018-09-27
HUE059774T2 (hu) 2023-01-28
US20250179080A1 (en) 2025-06-05
EP3439665A4 (en) 2019-11-27
EP3439665A1 (en) 2019-02-13
CA3016491A1 (en) 2017-09-21
JP2019509340A (ja) 2019-04-04
DK3439665T3 (da) 2022-09-26
EP4129297A1 (en) 2023-02-08
JP7023876B2 (ja) 2022-02-22
RS63674B1 (sr) 2022-11-30
PL3439665T3 (pl) 2023-01-16
US11753412B2 (en) 2023-09-12
ES2926918T3 (es) 2022-10-31
JP2022065035A (ja) 2022-04-26
US20240083905A1 (en) 2024-03-14
WO2017161370A1 (en) 2017-09-21
AU2022275446B2 (en) 2025-01-02
SI3439665T1 (sl) 2023-05-31
EP3439665B1 (en) 2022-06-29
SMT202200372T1 (it) 2022-11-18
US20210309662A1 (en) 2021-10-07
CY1125576T1 (el) 2026-02-25
LT3439665T (lt) 2022-10-10
WO2017161370A8 (en) 2018-09-27
US12180216B2 (en) 2024-12-31
AU2022275446A1 (en) 2023-01-05
US20200181146A1 (en) 2020-06-11
JP7515526B2 (ja) 2024-07-12
PT3439665T (pt) 2022-09-27
HRP20221098T1 (hr) 2022-11-25
US10906909B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
AU2022275446B2 (en) Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAa receptor agonists
ES2942308T3 (es) Compuestos y su uso como inhibidores de BACE1
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP5874878B2 (ja) 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
EA022649B1 (ru) ПРОИЗВОДНЫЕ 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
CA2934553A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019011924A2 (pt) derivados de bis-heteroarila bicíclicos como moduladores de agregação de proteína
KR20160130778A (ko) 고인슐린혈증과 관련된 질환의 치료
AU2021200164A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2010256360A1 (en) Aminopyrrolidinone derivatives and uses thereof
US10259815B2 (en) Gabaergic ligands and their uses
CA2935985A1 (en) Organic compounds
JP2022529814A (ja) 腎臓病の治療のための新規化合物及びその医薬組成物
US20240374612A1 (en) Imidazobenzodiazepines for treatment of cognitive and mood symptoms
CN105636943A (zh) 作为TCR-Nck相互作用的抑制剂的色烯衍生物
JP7738924B2 (ja) 新規ｖｄａｃ１阻害剤
HK1225379A1 (en) Chromene derivatives as inhibitors of tcr-nck interaction
HK1225379B (en) Chromene derivatives as inhibitors of tcr-nck interaction

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)